"This (approval of Covaxin) is excellent news. WHO follows stringent guidelines - a lot of data points need to be submitted. We should not overreact to the delay in its approval," says Biocon's Executive Chairperson Kiran Mazumdar Shaw.
from Videos https://ift.tt/3nVryYn
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment